The effect of Palivizumab in the incidence rate of hospitalisation for Respiratory Syncytial Virus infection in high-risk preterm infants in Doha, Qatar: three-year retrospective

被引：0
|
作者：
Elmasoudi, Ahmed [1 ]
Robson, Tracy [2 ]
Badran, Hoda [1 ]
Khalil, Ahmed [1 ]
机构：
[1] Hamad Gen Hosp, Dept Pharm, Doha, Qatar
[2] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland
来源：
PHARMACOTHERAPY | 2015年 / 35卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
323
引用
收藏
页码：E255 / E255
页数：1
相关论文
共 39 条
  • [1] Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants
    Vogel, AM
    Lennon, DR
    Broadbent, R
    Byrnes, CA
    Grimwood, K
    Mildenhall, L
    Richardson, V
    Rowley, S
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2002, 38 (06) : 550 - 554
  • [2] Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: A note of caution
    Suresh, S
    Schilling, S
    Dakin, C
    Harris, MA
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2003, 39 (08) : 637 - 637
  • [3] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    Null, D
    Bimle, C
    Weisman, L
    Johnson, K
    Steichen, J
    Singh, S
    Wang, E
    Asztalos, E
    Loeffler, AM
    Azimi, PH
    Lieberman, JM
    O'Donnell, NE
    Cooke, RJ
    McCormick, K
    Koo, W
    Hammami, M
    Milner, AD
    Gaon, P
    Nachman, S
    Tarpey, KP
    Sánchez, PJ
    Broyles, RS
    Bratcher, D
    Ball, MV
    Duda, FJ
    DeCuir, PM
    Pollara, B
    Nelson, LS
    Balbus, M
    Schultz, MJ
    Chipps, BE
    Givner, LB
    O'Shea, M
    Everard, M
    Pfeffer, K
    Page, AJ
    Dennehy, PH
    Modlin, J
    Rhodes, T
    DeVincenzo, N
    Nickerson, B
    Arrieta, A
    Boucher, FD
    Keeney, RE
    Young, TE
    Stevens, JC
    Ariagno, R
    Adams, M
    Polak, MJ
    Lynch, SK
    [J]. PEDIATRICS, 1998, 102 (03) : 531 - 537
  • [4] Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands
    Schepp, Rutger M.
    Kaczorowska, Joanna
    van Gageldonk, Pieter G. M.
    Rouers, Elsbeth D. M.
    Sanders, Elisabeth A. M.
    Bruijning-Verhagen, Patricia C. J.
    Berbers, Guy A. M.
    [J]. VACCINES, 2023, 11 (12)
  • [5] Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
    Mejias, Asuncion
    Ramilo, Octavio
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03): : 433 - 439
  • [6] Cost-effectiveness analysis of palivizumab for respiratory syncytial virus infection in high-risk infants in Japan
    Ikeda, S.
    Kobayashi, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A170 - A170
  • [7] Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
    Viguria, Natividad
    Navascues, Ana
    Juanbeltz, Regina
    Echeverria, Alberto
    Ezpeleta, Carmen
    Castilla, Jesus
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (06) : 1867 - 1872
  • [8] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB AS A PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK LATE PRETERM INFANTS IN THE NETHERLANDS
    Langenfeld, M. K.
    Visser, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A372 - A372
  • [9] The frequency of respiratory syncytial virus in high risk infants and the role of palivizumab in prevention of infection
    Tom, CM
    Touch, SM
    Stanley, C
    Frey, B
    McNett, W
    Desai, SA
    [J]. PEDIATRICS, 1999, 104 (03) : 736 - 737
  • [10] A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan
    Chi, Hsin
    Hsu, Chyong-Hsin
    Chang, Jui-Hsing
    Chiu, Nan-Chang
    Hung, Han-Yang
    Kao, Hsin-An
    Weng, Li-Chuan
    Huang, Fu-Yuan
    Chiu, Yu-Ying
    Chang, Luan-Yin
    Huang, Li-Min
    [J]. PLOS ONE, 2014, 9 (06):
1234